about
Implications of recent insights into the pathophysiology of paroxysmal nocturnal haemoglobinuria.Monoclonal B lymphocytes with the characteristics of "indolent" chronic lymphocytic leukemia are present in 3.5% of adults with normal blood counts.Laboratory diagnosis of acute myeloid leukaemia.Monoclonal B-cell lymphocytosis and chronic lymphocytic leukemia.The role of flow cytometry in the diagnosis of paroxysmal nocturnal hemoglobinuria in the clinical laboratory.Standardization of flow cytometry in myelodysplastic syndromes: report from the first European LeukemiaNet working conference on flow cytometry in myelodysplastic syndromes.Chronic FLT3-ITD Signaling in Acute Myeloid Leukemia Is Connected to a Specific Chromatin Signature.CD4 cell counts used as surrogate test for HIV infection.In multiple myeloma, only a single stage of neoplastic plasma cell differentiation can be identified by VLA-5 and CD45 expression.Development and progression of a Philadelphia-chromosome-negative acute myelocytic leukemia clone in a patient with Philadelphia-chromosome-positive chronic myelocytic leukemia.Under-recognized complications in patients with paroxysmal nocturnal haemoglobinuria: raised pulmonary pressure and reduced right ventricular function.Guidelines for the diagnosis and monitoring of paroxysmal nocturnal hemoglobinuria and related disorders by flow cytometry.Diagnosis of plasma cell leukaemia: findings of the UK NEQAS for Leucocyte Immunophenotyping scheme.Introduction to ICCS/ESCCA consensus guidelines to detect GPI-deficient cells in paroxysmal nocturnal hemoglobinuria and related disorders.Influence of laparoscopic and conventional cholecystectomy upon cell-mediated immunity.High-Sensitivity Detection of PNH Red Blood Cells, Red Cell Precursors, and White Blood Cells.Standardizing leucocyte PNH clone detection: an international study.Development and evaluation of a stabilized whole-blood preparation as a process control material for screening of paroxysmal nocturnal hemoglobinuria by flow cytometry.Erythopoietin treatment during complement inhibition with eculizumab in a patient with paroxysmal nocturnal hemoglobinuria.Early prediction of outcome and response to alemtuzumab therapy in chronic lymphocytic leukemia.Concurrent treatment of aplastic anemia/Paroxysmal Nocturnal Hemoglobinuria syndrome with immunosuppressive therapy and eculizumab: a UK experience.A pilot study of combination anti-cytokine and anti-lymphocyte biological therapy in rheumatoid arthritis.Inherited predisposition to CLL is detectable as subclinical monoclonal B-lymphocyte expansion.High-producer haplotypes of tumor necrosis factor alpha and lymphotoxin alpha are associated with an increased risk of myeloma and have an improved progression-free survival after treatment.The PNH phenotype cells that emerge in most patients after CAMPATH-1H therapy are present prior to treatment.Trisomy 12 is seen within a specific subtype of B-cell chronic lymphoproliferative disease affecting the peripheral blood/bone marrow and co-segregates with elevated expression of CD11a.Circulating plasma cells in multiple myeloma: characterization and correlation with disease stage.Immunophenotypic and DNA genotypic analysis of T-cell and NK-cell subpopulations in patients with B-cell chronic lymphocytic leukaemia (B-CLL).Persistent clonal expansions of CD3+TCR gamma delta+ and CD3+TCR alpha beta+CD4-CD8- lymphocytes associated with neutropenia.Immunophenotypic Dissection of Normal Peripheral Blood NK Associated (NKa) Subpopulations by Flow Cytometry: Morphological Features and Relationships Between Membrane NKa (CD11b, CD 16, CD56 and CD57) arid T-cell (CD2, CD3, TCR, CD5, CD7, CD8 and CDHypomorphic promoter mutation in PIGM causes inherited glycosylphosphatidylinositol deficiencyA phase 1 study to address the safety and efficacy of granulocyte colony-stimulating factor for the mobilization of hematopoietic progenitor cells in active rheumatoid arthritisSignificant hemolysis is not required for thrombosis in paroxysmal nocturnal hemoglobinuriaStandardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working GroupSubtype-specific regulatory network rewiring in acute myeloid leukemia.A distinct large granular lymphocyte (LGL)/NK-associated (NKa) abnormality characterized by membrane CD4 and CD8 coexpression. The Yorkshire Leukaemia GroupLarge granular lymphocytesDiagnostic application of monoclonal antibody KB90 (CD11c) in acute myeloid leukaemiaTransient and persistent expansions of large granular lymphocytes (LGL) and NK-associated (NKa) cells: the Yorkshire Leukaemia Group StudyClonal CD3+CD8+ large granular lymphocyte (LGL)/NK-associated (NKa) expansions: primary malignancies or secondary reactive phenomena?
P50
Q33888594-1432C70E-3BFB-416D-BF60-60991B9EB3B6Q34136266-2CF300C3-DBBD-411E-9430-98BF50A98099Q34252824-31E56542-C88B-44B6-A8BA-1892A914589DQ34805491-B06FD8A8-322C-478B-9F9E-52E21FC7A0D0Q36894049-764F80F6-A96C-468E-BECF-D3207716EB5EQ39968886-09435FFE-D924-410D-A493-2E2DCFBCA658Q41089332-F7306602-FAEA-4A38-8DD2-338A6AF74E72Q42876567-F8C2C2F8-6A57-485B-AD5E-15B70278B53DQ43622762-777511F9-6F27-45A6-B820-F3C34A152117Q44735598-983FDCC0-BFDF-41D2-B909-B0A58160E9BBQ45085693-6B92E6C5-33A1-44A2-AF90-D15AEA21BD0BQ45340511-9344E3C7-584C-48E5-8B26-3A9A711E0A14Q47248792-2CFD43E5-34A2-4053-93E4-844688679881Q49496862-93EB4588-23E3-403A-9644-2DD87C66E1B0Q50174699-C47EE096-8B4F-4331-B79A-B4C441C9EFE0Q50449096-E2CB484F-FF98-4C0B-8B1D-C2B046C7FBF0Q50474440-E9A44C85-69F9-4D79-8B6E-9231980B43DBQ50635749-C89ED9DA-DDF4-4724-A834-4C86C886FB3BQ50700064-C5A6B2C2-5BFB-49AE-AA3D-6B6EB1658009Q52007715-B41FC4FF-F4F9-4784-8596-1535E525AF79Q52802804-515ECF0E-3108-45CA-8FCD-0ED799CCA846Q52852039-DB9E0971-E68B-4E07-A96F-FCE6586615DAQ52861140-2B4D1288-7533-4CBE-A98B-8EFD7E4424C9Q52863875-C2AED847-2171-47B7-837C-4FDB1E90556CQ52865040-923E4DBB-F7DC-4187-8C6C-B28CE35656E4Q52867196-DA923BD1-2D46-4CDD-8101-09B709B2EAFCQ52868194-DCFAB747-7F13-4840-93AC-7001DE9D0FD7Q52870986-6DD58277-C40C-4696-BA10-8B18CBB52FD0Q52871500-E5D016E2-F7A7-48FE-803A-920EB75859D7Q52875915-0A21733B-4ABA-4119-89F7-C322609524A8Q55671185-6AC630FA-11DC-4A4E-97C3-E2795D8BB8A6Q56462138-7200E3EC-523C-4DCC-AA8F-13D4D4416890Q57027147-7409BDE6-B7B1-4B23-AF0B-10DB0DCEDD66Q63346979-E5C255A0-5ECA-41D8-8B82-D231D8B64244Q64911185-3960373E-1D93-4774-A572-F4156E620B28Q67525682-C5B83978-097C-4F4E-9C00-99C85230CA3EQ68319346-426E4637-E8BB-4B19-97D3-6C212953C98DQ69102807-0723097D-4C3A-4590-A51F-8B3995DE0934Q70689263-C46816B7-62F3-4423-AD0C-86E561D0E50CQ70949273-AB6A76C0-15F2-415C-885C-4B460F78ACEF
P50
description
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Stephen J Richards
@ast
Stephen J Richards
@en
Stephen J Richards
@es
Stephen J Richards
@nl
type
label
Stephen J Richards
@ast
Stephen J Richards
@en
Stephen J Richards
@es
Stephen J Richards
@nl
prefLabel
Stephen J Richards
@ast
Stephen J Richards
@en
Stephen J Richards
@es
Stephen J Richards
@nl
P106
P1153
7202128560
P31
P496
0000-0002-8421-5353